Emcure Pharmaceuticals Ltd · EMCURE · Pharma - Formulators · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 3 November 2026
Emcure Pharmaceuticals share price today: ₹2,334.80 at the close on 18 November 2026, up 72.4% in a year. Emcure Pharmaceuticals (EMCURE) is worth ₹44,288 crore, trades at a P/E of 40.5 and has closed between ₹1,354.60 and ₹2,361.70 over the past 52 weeks. Latest change: revenue up on a year earlier for 10 quarters in a row (every quarter we can compare).
Emcure Pharmaceuticals Ltd's share price has risen faster than its earnings: +72.4% in a year, against +37.7% for earnings per share.
The main question: the share price moved +72.4% in a year while earnings per share (last four quarters) moved +37.7%. The difference came from the market paying a higher multiple.
The price has been rising for 71 weeks, and the P/E is higher than 77% of its own last 2.3 years. Over the last four quarters, results have been improving, with profit +29.5% on a year earlier, and 133% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.
Left out of this page: Its two data sources disagree by up to 7.2% on reported income across 14 comparable periods, so nothing from the second source is shown here. That is why the PEG ratio and its quarterly curve, the yearly return-on-capital-used (ROIC) line, the total-debt and debt-to-equity series and the F-score and the return-on-capital-used (ROIC) reading are missing. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.
What is the Emcure Pharmaceuticals share price today?
Emcure Pharmaceuticals Ltd's share price was ₹2,334.80 at the close on 18 November 2026. It has been rising for 71 weeks. That is 30.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,355 and ₹2,362, and at that close it sat 97% of the way up from that low.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Emcure Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.
Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 5 weeks in a row.
Week by week since 2024: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 86 of 119 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 12 Jul 2024 | no NIFTY 500 reading |
| 19 Jul 2024 | no NIFTY 500 reading |
| 26 Jul 2024 | no NIFTY 500 reading |
| 2 Aug 2024 | no NIFTY 500 reading |
| 9 Aug 2024 | no NIFTY 500 reading |
| 16 Aug 2024 | no NIFTY 500 reading |
| 23 Aug 2024 | no NIFTY 500 reading |
| 30 Aug 2024 | no NIFTY 500 reading |
| 6 Sep 2024 | no NIFTY 500 reading |
| 13 Sep 2024 | no NIFTY 500 reading |
| 20 Sep 2024 | no NIFTY 500 reading |
| 27 Sep 2024 | no NIFTY 500 reading |
| 4 Oct 2024 | no NIFTY 500 reading |
| 11 Oct 2024 | +5.5% |
| 18 Oct 2024 | +8.0% |
| 25 Oct 2024 | +9.0% |
| 1 Nov 2024 | +12.8% |
| 8 Nov 2024 | +9.5% |
| 14 Nov 2024 | +12.6% |
| 22 Nov 2024 | +0.0% |
| 29 Nov 2024 | +1.2% |
| 6 Dec 2024 | −1.1% |
| 13 Dec 2024 | −2.0% |
| 20 Dec 2024 | +2.5% |
| 27 Dec 2024 | +7.1% |
| 3 Jan 2025 | +6.2% |
| 10 Jan 2025 | +0.2% |
| 17 Jan 2025 | −1.3% |
| 24 Jan 2025 | −1.0% |
| 1 Feb 2025 | −7.8% |
| 7 Feb 2025 | −8.6% |
| 14 Feb 2025 | −20.7% |
| 21 Feb 2025 | −17.3% |
| 28 Feb 2025 | −15.7% |
| 7 Mar 2025 | −16.8% |
| 13 Mar 2025 | −18.2% |
| 21 Mar 2025 | −20.4% |
| 28 Mar 2025 | −20.5% |
| 4 Apr 2025 | −24.2% |
| 11 Apr 2025 | −27.5% |
| 17 Apr 2025 | −19.3% |
| 25 Apr 2025 | −22.3% |
| 2 May 2025 | −20.3% |
| 9 May 2025 | −17.1% |
| 16 May 2025 | −3.8% |
| 23 May 2025 | +18.9% |
| 30 May 2025 | +20.8% |
| 6 Jun 2025 | +23.4% |
| 13 Jun 2025 | +33.2% |
| 20 Jun 2025 | +19.3% |
| 27 Jun 2025 | +10.5% |
| 4 Jul 2025 | +13.6% |
| 11 Jul 2025 | +28.9% |
| 18 Jul 2025 | +17.1% |
| 25 Jul 2025 | +31.4% |
| 1 Aug 2025 | +30.7% |
| 8 Aug 2025 | +34.0% |
| 14 Aug 2025 | +37.5% |
| 22 Aug 2025 | +15.3% |
| 29 Aug 2025 | +6.3% |
| 5 Sep 2025 | +4.9% |
| 12 Sep 2025 | −2.2% |
| 19 Sep 2025 | +0.4% |
| 26 Sep 2025 | +2.6% |
| 3 Oct 2025 | +9.3% |
| 10 Oct 2025 | +9.5% |
| 17 Oct 2025 | −2.8% |
| 24 Oct 2025 | −6.5% |
| 31 Oct 2025 | −7.9% |
| 7 Nov 2025 | −6.5% |
| 14 Nov 2025 | −10.8% |
| 21 Nov 2025 | −12.8% |
| 28 Nov 2025 | −5.0% |
| 5 Dec 2025 | −2.7% |
| 12 Dec 2025 | +4.3% |
| 19 Dec 2025 | +2.4% |
| 26 Dec 2025 | +6.5% |
| 2 Jan 2026 | +2.1% |
| 9 Jan 2026 | +7.7% |
| 16 Jan 2026 | +16.1% |
| 23 Jan 2026 | +16.9% |
| 1 Feb 2026 | +15.3% |
| 6 Feb 2026 | +11.6% |
| 13 Feb 2026 | +10.7% |
| 20 Feb 2026 | +7.8% |
| 27 Feb 2026 | +6.1% |
| 6 Mar 2026 | +7.1% |
| 13 Mar 2026 | +9.8% |
| 20 Mar 2026 | +16.7% |
| 27 Mar 2026 | +27.3% |
| 2 Apr 2026 | +21.3% |
| 10 Apr 2026 | +8.7% |
| 17 Apr 2026 | +9.9% |
| 24 Apr 2026 | +7.6% |
| 30 Apr 2026 | +14.8% |
| 8 May 2026 | +9.8% |
| 15 May 2026 | +17.9% |
| 22 May 2026 | +22.4% |
| 29 May 2026 | +18.7% |
| 4 Jun 2026 | +23.3% |
| 5 Jun 2026 | +17.1% |
| 9 Jun 2026 | +12.1% |
| 10 Jun 2026 | −2.8% |
| 12 Jun 2026 | +4.3% |
| 17 Jun 2026 | +4.3% |
| 19 Jun 2026 | +5.0% |
| 24 Jun 2026 | +10.0% |
| 25 Jun 2026 | +10.0% |
| 1 Jul 2026 | +10.6% |
| 3 Jul 2026 | +4.5% |
| 10 Jul 2026 | +2.8% |
| 17 Jul 2026 | +2.1% |
| 24 Jul 2026 | +5.8% |
| 31 Jul 2026 | +7.1% |
| 7 Aug 2026 | +8.5% |
| 14 Aug 2026 | +7.2% |
| 21 Aug 2026 | +3.2% |
| 28 Aug 2026 | +6.7% |
| 4 Sep 2026 | +8.1% |
| 11 Sep 2026 | +8.6% |
| 18 Sep 2026 | +7.8% |
| 25 Sep 2026 | +9.5% |
| 28 Sep 2026 | +7.8% |
| 1 Oct 2026 | +13.6% |
| 9 Oct 2026 | +9.1% |
| 16 Oct 2026 | −0.4% |
| 23 Oct 2026 | −1.0% |
| 30 Oct 2026 | +2.3% |
| 6 Nov 2026 | +15.1% |
| 8 Nov 2026 | +22.7% |
| 13 Nov 2026 | +25.5% |
| 18 Nov 2026 | +19.1% |
Over the last 2.3 years the share price moved +71% while the NIFTY 500 moved +3%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at Emcure Pharmaceuticals this quarter?
Three changes stood out: revenue up on a year earlier for 10 quarters in a row (every quarter we can compare), profit up on a year earlier for 10 quarters in a row (every quarter we can compare) and highest quarterly profit in 14 quarters.
Revenue up on a year earlier for 10 quarters in a row (every quarter we can compare)
In the September 2026 quarter revenue was ₹2,820 crore, +24.2% on a year earlier.
Profit up on a year earlier for 10 quarters in a row (every quarter we can compare)
In the September 2026 quarter profit was ₹325 crore, +29.5% on a year earlier.
Highest quarterly profit in 14 quarters
Profit of ₹325 crore in the September 2026 quarter is the highest of the last 14 quarters.
What are Emcure Pharmaceuticals' latest quarterly results?
For July to September 2026 (the quarter ended 30 September 2026), Emcure Pharmaceuticals reported revenue of ₹2,820 crore, up 24.2% from ₹2,270 crore a year earlier, and a profit of ₹325 crore, up 29.5% from ₹251 crore.
Emcure Pharmaceuticals results: July to September 2026 against a year earlier
| Measure | July to September 2026 | July to September 2025 | Change |
|---|---|---|---|
| Revenue | ₹2,820 crore | ₹2,270 crore | +24.2% |
| Profit | ₹325 crore | ₹251 crore | +29.5% |
| Earnings per share | ₹17.16 | ₹12.84 | +33.6% |
| Operating margin | 20.9% | 20.9% | 0.0 points |
The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
Emcure Pharmaceuticals' management discussed these results on a call held on 3 November 2026; what it said is further down this page.
From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.
What is the Emcure Pharmaceuticals share price history?
Emcure Pharmaceuticals closed at ₹2,334.80 on 18 November 2026, up 72.4% from ₹1,354.60 a year earlier (21 November 2025). Its highest weekly close since July 2024 was ₹2,361.70 on 13 November 2026.
Emcure Pharmaceuticals share price: then and now
| When | Close | Change to 18 Nov 2026 |
|---|---|---|
| 1 week ago · 11 Nov 2026 | ₹2,232.40 | +4.6% |
| 1 month ago · 19 Oct 2026 | ₹1,766.60 | +32.2% |
| 6 months ago · 15 May 2026 | ₹1,704.90 | +36.9% |
| 1 year ago · 21 Nov 2025 | ₹1,354.60 | +72.4% |
| Earliest weekly close in our records · 12 Jul 2024 | ₹1,362.45 | +71.4% |
| Highest weekly close since July 2024, also the 52-week high · 13 Nov 2026 | ₹2,361.70 | −1.1% |
| Lowest weekly close since July 2024 · 11 Apr 2025 | ₹919.45 | +153.9% |
| 52-week low (weekly close) · 21 Nov 2025 | ₹1,354.60 | +72.4% |
Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
132 weekly closes from 12 July 2024 to 18 November 2026.
What is the latest news on Emcure Pharmaceuticals?
18 Nov 2026: Emcure Pharmaceuticals closed at ₹2,334.80, up 4.6% on the week and up 32.2% on the month. 3 Nov 2026: Emcure Pharmaceuticals held its results call for July to September 2026. Management guided: FY27 consolidated revenue growth above 20%.
Earlier
- Results for July to September 2026: Revenue up 24.2% and profit up 29.5% on a year earlier.
- 4 Sep 2026: ex-date for a dividend of ₹3.60 a share.
What dividend does Emcure Pharmaceuticals pay?
Emcure Pharmaceuticals paid ₹3.60 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.15% at the ₹2,334.80 close on 18 November 2026. The last was a dividend of ₹3.60 a share, ex-date 4 September 2026.
Emcure Pharmaceuticals dividends since 1 April 2021
| Ex-date | Dividend per share | Type |
|---|---|---|
| 4 Sep 2026Dividend | ₹3.60 | Dividend |
| 14 Aug 2025Dividend | ₹3 | Dividend |
Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.
Yes. Emcure Pharmaceuticals Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in each of its last 8 reported years.
From the exchange corporate-actions record, read 18 November 2026.
What did Emcure Pharmaceuticals management say on the latest results call?
On the call for July to September 2026, held on 3 November 2026, Emcure Pharmaceuticals' management guided: FY27 consolidated revenue growth above 20%.
“We now expect revenue growth to exceed 20% compared with the mid-teens that we indicated earlier.”Satish Mehta, on the call for July to September 2026
What management guided
- FY27 operating margin expansion 75-100 basis points with bias to upper end on operating leverage.
- FY27 R and D at 4-5% of revenue with H2 step-up from H1 level.
- Domestic full-year low-teens growth with exit at or above industry on organic basis.
- Net cash by end FY28 commitment reaffirmed after acquisition-related payouts.
Management’s own plans and goals, from our notes of the call. A plan is not a result.
Source: the call transcript.
From the call for July to September 2026, 3 November 2026.
What to watch in Emcure Pharmaceuticals' next results?
When Emcure Pharmaceuticals reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Domestic growth to reach industry parity by exit at flagged full-year threshold - compare Q3 print and IPM.
Management raised each of these on the latest results call.
- Domestic growth to reach industry parity by exit at flagged full-year threshold - compare Q3 print and IPM.
- Net-debt reduction to stay on net-cash path after deal payouts - check Q3 balance sheet and payout updates.
Which stock lists is Emcure Pharmaceuticals on?
Emcure Pharmaceuticals is on 4 of our India lists: Momentum stocks, 52 week high & low, Small & mid cap stocks and Pharma stocks.
Is Emcure Pharmaceuticals profitable?
Emcure Pharmaceuticals Ltd earned ₹325 Cr of net profit in the Sep 2026 quarter, +29.5% on the same quarter a year earlier. That is the 10th quarter in a row of profit growth. Full-year FY26 profit was ₹941 Cr. Over 7 years profit has grown 24.0% a year on average. The same quarter a year earlier earned ₹251 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
The Sep 2026 quarter's profit is 11.5% of that quarter's revenue.
For the full year, FY26 profit was ₹941 Cr (+33.1% on the year before).
Why profit moved: revenue changed +24.2% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.
On average over the last four quarters, profit changed +34.3% and revenue +21.0%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.
FY27-Q1. revenue ₹2,580 Cr and profit ₹292 Cr as reported.
FY27-Q2. revenue ₹2,820 Cr and profit ₹325 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
How much revenue does Emcure Pharmaceuticals make, and is it growing?
Emcure Pharmaceuticals Ltd reported ₹2,820 Cr of revenue in the Sep 2026 quarter, +24.2% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 7 years it has grown 10.0% a year on average. The last full year, FY26, came in at ₹9,204 Cr.
Revenue is everything the company billed its customers in the period.
The last four reported quarters add to ₹10,233 Cr.
FY26 revenue was ₹9,204 Cr, +16.6% on the year before.
Recent pace: the last four quarters grew +21.0% on average, against 10.0% a year over the longer run, so this year is growing faster than its own long-run rate.
Is growth speeding up? Revenue over the last 12 months grew +21.1%, against +18.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +33.3%, against +35.4% a year (stabilising).
FY27-Q1. revenue ₹2,580 Cr and profit ₹292 Cr as reported.
FY27-Q2. revenue ₹2,820 Cr and profit ₹325 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
How much of every ₹100 of sales does Emcure Pharmaceuticals keep?
Emcure Pharmaceuticals Ltd's operating margin was 20.9% in the Sep 2026 quarter, about the same as the same quarter a year ago. Across 8 years it has been between 14.0% and 24.2%. The latest quarter is within that range.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.
Why the margin moved: operating margin changed −0.1 percentage points on the year while gross margin changed −1.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged.
FY27-Q1. revenue ₹2,580 Cr and profit ₹292 Cr as reported.
FY27-Q2. revenue ₹2,820 Cr and profit ₹325 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Is Emcure Pharmaceuticals' profit turning into cash?
Over the last 3 years, 133% of Emcure Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹944 Cr of operating cash against ₹941 Cr of profit. After ₹361 Cr of spending on assets, ₹583 Cr was left over as free cash.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 133% of profit came in as cash: the cash cycle got 51 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.
What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.
Where does Emcure Pharmaceuticals' cash go?
Emcure Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 161 days in FY26, down from 212 days in FY21. It spent ₹859 Cr on assets over the last 3 years. Customers take 102 days to pay, and stock sits for 239 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹9,204 Cr, each day of that cycle ties up about ₹25.2 Cr, so roughly ₹4,060 Cr is tied up in the business at any time.
FY26: customers took 102 days to pay and stock sat for 239 days, about 7.9 months of sales sitting as stock, for a full cycle of 161 days, shorter than FY21's 212.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 239 days. Customers pay about 102 days after that. Suppliers are paid at 180 days. Together that makes the 161-day cycle.
Spending on assets: ₹859 Cr over the last 3 years, against ₹1,111 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹273 Cr (FY26): assets paid for that are not earning yet.
In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.
What is Emcure Pharmaceuticals' P/E ratio, and how does it compare with its own history?
Emcure Pharmaceuticals Ltd's P/E is 40.5×, near the high end of its own history: higher than 77% of past readings. Its usual P/E (the middle reading) is 35.5×, over 2.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹57.66.
Why the multiple is where it is: over the past year earnings per share moved +37.7% while the price moved +72.4%. The price did better than earnings, which pushed the multiple up within its own range.
In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.
The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 7.2% on reported income across 14 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.
What growth does the Emcure Pharmaceuticals share price assume?
Worked out from its price on 24 August 2026, Emcure Pharmaceuticals Ltd's share price assumed profit growth of about 19.7% a year. Over the past 7 years its profit actually grew 24.0% a year. Today its P/E is 40.5×, higher than 77% of its own last 2.3 years.
This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.
This is a one-day reading, taken on 24 August 2026. Every other number on this page, the multiple included, uses the latest price as of 18 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.
Is the Emcure Pharmaceuticals business getting better or worse?
Emcure Pharmaceuticals Ltd's business is growing steadily. Revenue and profit growth have stayed positive throughout, and ROCE is steady at 24.3% (four quarters to Sep 2026). This is based on 10 quarters of 3 measures, with some gaps.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: steady growth with healthy returns is how a business compounds over time.
One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.
The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.
This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +16.6% | +15.4% | +12.8% | — |
| Profit | +33.1% | +18.7% | +17.6% | — |
| EPS | +35.6% | +18.3% | +16.1% | — |
| Share price | +72.4% | — | — | — |
What is the Emcure Pharmaceuticals story, and has it been checked?
Emcure Pharmaceuticals Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: Not stated in the research file.
NOT YET CHECKED
Our read, 22 August 2026. FY26 crossed the $1 billion revenue milestone with PAT up 33%;
What is not proven yet. Two consecutive quarters of domestic revenue below 8% YoY growth (after the Q1 FY27 recovery to 10.2%) would signal the Zuventus restructuring never fully normalized; and gross margin falling below 57% for two consecutive quarters, without management providing a segment-level explanation that fully accounts for the ARV mix, would signal pricing power erosion beyond the structural mix shift.
FY26-Q3FY27-Q2
What the surface reading misses. The surface reading is: Q3 FY26 PAT growth of 48.1% YoY appears to be an acceleration. The research reads it further: The Q3 FY26 PAT spike to 48.1% partly reflects a low base: Q3 FY25 PAT was Rs 156 Cr, which was below-trend due to integration costs from the Zuventus acquisition. The operating mechanism was real (EBITDA margin expanded 110 bps to 19.5% in Q3, driven by operating leverage and Semaglutide launch momentum), but the base effect explains roughly 15-20% of the apparent acceleration.
Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Did Emcure Pharmaceuticals management deliver what it promised?
What Emcure Pharmaceuticals Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
FY27 Revenue Guidance Materially Raised · 3 November 2026. In May 2026 and August 2026, management guided to low-to-mid-teen FY27 revenue growth. In November 2026, it raised the forecast to above 20%, a material revision of more than five percentage points; management cited strong first-half performance and international momentum, but the revised outlook should still be reconciled with the earlier plan.
Liposomal Amphotericin B European Footprint · 3 November 2026. The August 2026 call said the product was already introduced in pretty much all European countries and supplies were being ramped. In November 2026, management said about 20 countries still needed to be entered, creating a material inconsistency in the stated launch footprint and remaining growth runway with no explanation for the reversal.
Amphotericin B Pan-European Launch Scope Fell Short of Prior Commitments · 5 May 2026. In both the Nov 2025 and Feb 2026 calls, management explicitly committed to Amphotericin B launches across Europe by year-end FY26. The latest call (May 2026) confirms that only select European markets were covered in H2 FY26, with broader European and ROW expansion now deferred to FY27. No clear explanation was provided in the latest call for why the pan-European scope was not achieved as consistently promised across two prior calls.
Canada Semaglutide Strategy Pivots from Own Filing to Third-Party Partnership · 5 May 2026. The Nov 2025 call included an explicit on-record confirmation that plans to file Emcure's own semaglutide product in Canada by end of FY26 would proceed as planned. The latest call (May 2026) instead describes a near-term Canadian launch via a Dr. Reddy's distribution partnership for Quebec, while own-product commercialization is repositioned as a mid-term opportunity. The present-tense phrasing 'we are also filing' implies the end-of-FY26 filing commitment was not completed on schedule, and the near-term Canadian GLP-1 strategy has materially shifted from own-product to third-party without explanation.
Every quote above is taken word for word from the company’s own earnings calls.
What is Emcure Pharmaceuticals management's track record?
The record supports VERIFY: capital allocation and current reported delivery are sound, but promises on dates, products and debt-free timing need discounting.
Regulatory and governance record
The sweep found a small 2025 Companies Act compounding fee, a current employee-poaching suit brought by Emcure, and an old 2019 FDA warning; no current SEBI fraud action surfaced.
Checked 30 August 2026.
How much does Emcure Pharmaceuticals earn on its capital?
Emcure Pharmaceuticals Ltd earned a ROCE of 24% in FY26. That is up from a low of 11% in FY20. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 10.2% net margin and 0.97× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Why the return is what it is (FY26): a 10.2% net margin × 0.97× asset turnover × 1.92× leverage (assets divided by equity) ≈ 19.0% on equity. The margin does its share; borrowing is a big part of it.
The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 7.2% on reported income across 14 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.
Does Emcure Pharmaceuticals have too much debt?
Emcure Pharmaceuticals Ltd had ₹1,521 Cr of borrowings against ₹4,950 Cr of equity in FY26, so its debt is 0.31× its equity. Its operating profit is 12 times its interest bill. Over 5 years borrowings went from ₹2,310 Cr to ₹1,521 Cr. Over the last 3 of those years it spent ₹859 Cr on assets.
Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.
The spending on assets is being paid for from cash, not new debt.
The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 7.2% on reported income across 14 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.
What is the Emcure Pharmaceuticals shareholding pattern?
Domestic institutions raised their stake in Emcure Pharmaceuticals Ltd by 4.5 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 8.5% of the company. Foreign institutions moved +2.0 points over the same period, to 4.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
Over the last two years: Domestic institutions: +4.5 points over 8 quarters, to 8.5%; Foreign institutions: +2.0 points over 8 quarters, to 4.9%; Promoters: −0.3 points over 8 quarters, to 77.8%.
Why the owners changed: domestic institutions drove it (+4.5 points), together with foreign institutions (+2.0 points). They raised their stake step by step.
How far is Emcure Pharmaceuticals from balance-sheet trouble?
For Emcure Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does Emcure Pharmaceuticals rank in its industry?
72.8 out of 100, rank 2 of 44 in Pharma - Formulators, with 75% of the evidence available.
Emcure Pharmaceuticals Ltd scores 72.8 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 2. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
The four parts add up to the total exactly: 26.1 + 18 + 10 + 18.7 = 72.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Emcure Pharmaceuticals compared with?
Emcure Pharmaceuticals ranks 2 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 72.8 out of 100.
- 1Marksans Pharma LtdMARKSANS · losing its lead · Most evidence points up · 78% evidence75.8out of 100
How the score adds up
Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidenceValuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks aheadExact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Emcure Pharmaceuticals Ltd this pageEMCURE · leader · Most evidence points up · 75% evidence72.8out of 100
How the score adds up
Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidenceCapital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidenceValuation 10.0/20 · P/E 40.5× · PEG — · 15% evidenceRelative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 3Kwality Pharmaceuticals LtdKPL · breaking out · Most evidence points up · 75% evidence68.3out of 100
How the score adds up
Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidenceCapital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidenceValuation 6.5/20 · P/E 45.5× · PEG — · 50% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks aheadExact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 4Rubicon Research LtdRUBICON · losing its lead · Most evidence points up · 87% evidence67.4out of 100
How the score adds up
Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidenceCapital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidenceValuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidenceRelative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks aheadExact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 5Accent Microcell LtdACCENTMIC · losing its lead · Most evidence points up · 65% evidence66.2out of 100
How the score adds up
Growth & earnings 21.8/35 · Revenue — · Profit — · Operating margin change 7 points · 27% evidenceCapital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidenceValuation 10.1/20 · P/E 25.6× · PEG — · 50% evidenceRelative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks aheadExact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Ajanta Pharma LtdAJANTPHARM · quiet · Most evidence points up · 100% evidence65.7out of 100
How the score adds up
Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidenceCapital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidenceValuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidenceRelative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. - 7Mankind Pharma LtdMANKIND · turning · Most evidence points up · 100% evidence65.3out of 100
How the score adds up
Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidenceRelative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks aheadExact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Bliss GVS Pharma LtdBLISSGVS · leader · Most evidence points up · 82% evidence65.3out of 100
How the score adds up
Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidenceCapital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidenceValuation 6.5/20 · P/E 44.8× · PEG — · 50% evidenceRelative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Alembic Pharmaceuticals LtdAPLLTD · leader · Evidence leans up · 85% evidence64.0out of 100
How the score adds up
Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidenceCapital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidenceValuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidenceRelative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks aheadExact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10Ipca Laboratories LtdIPCALAB · leader · Evidence leans up · 82% evidence62.4out of 100
How the score adds up
Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidenceCapital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 11.7/20 · P/E 33.5× · PEG — · 50% evidenceRelative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Fredun Pharmaceuticals LtdFREDUN · losing its lead · Evidence leans up · 70% evidence61.2out of 100
- 12FDC LtdFDC · turning · Evidence leans up · 75% evidence59.2out of 100
- 13Aurobindo Pharma LtdAUROPHARMA · leader · Evidence leans up · 100% evidence58.9out of 100
- 14Corona Remedies LtdCORONA · breaking out · Evidence leans up · 73% evidence58.3out of 100
- 15Lupin LtdLUPIN · quiet · Evidence leans up · 90% evidence57.2out of 100
- 16Gufic BioSciences LtdGUFICBIO · leader · Evidence leans up · 75% evidence56.8out of 100
- 17ERIS Lifesciences LtdERIS · basing · Evidence leans up · 67% evidence56.0out of 100
- 18Kilitch Drugs (India) LtdKILITCH · turning · Evidence leans up · 82% evidence55.8out of 100
- 19Caplin Point Laboratories LtdCAPLIPOINT · quiet · Evidence leans up · 90% evidence55.2out of 100
- 20Wockhardt LtdWOCKPHARMA · losing its lead · Evidence leans up · 83% evidence54.7out of 100
- 21Influx Healthtech LtdINFLUX · quiet · Evidence leans up · 63% evidence54.3out of 100
- 22Amrutanjan Health Care LtdAMRUTANJAN · breaking out · Evidence leans up · 90% evidence54.1out of 100
- 23Akums Drugs & Pharmaceuticals LtdAKUMS · losing its lead · Evidence leans up · 75% evidence53.3out of 100
- 24Strides Pharma Science LtdSTAR · breaking out · Evidence leans up · 82% evidence52.3out of 100
- 25Zydus Lifesciences LtdZYDUSLIFE · breaking out · Evidence leans up · 90% evidence51.5out of 100
- 26Glenmark Pharmaceuticals LtdGLENMARK · breaking out · Evidence leans up · 90% evidence50.6out of 100
- 27Bafna Pharmaceuticals LtdBAFNAPH · breaking out · Evidence leans down · 68% evidence49.1out of 100
- 28Alkem Laboratories LtdALKEM · quiet · Evidence leans down · 82% evidence48.3out of 100
- 29J B Chemicals & Pharmaceuticals LtdJBCHEPHARM · Too little evidence to rank firmly · 59% evidence45.8out of 100
- 30Bharat Parenterals LtdBPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence45.8out of 100
- 31Zim Laboratories LtdZIMLAB · leader · Evidence leans down · 74% evidence42.8out of 100
- 32Bajaj Healthcare LtdBAJAJHCARE · basing · Evidence leans down · 90% evidence42.7out of 100
- 33Lincoln Pharmaceuticals LtdLINCOLN · quiet · Evidence leans down · 90% evidence41.5out of 100
- 34Sun Pharmaceutical Industries LtdSUNPHARMA · quiet · Evidence leans down · 100% evidence39.8out of 100
- 35RPG Life Sciences LtdRPGLIFE · losing its lead · Evidence leans down · 90% evidence38.9out of 100
- 36Indoco Remedies LtdINDOCO · turning · Too little evidence to rank firmly · 52% evidence37.8out of 100
- 37Suven Life Sciences LtdSUVEN · quiet · Most evidence points down · 67% evidence34.4out of 100
- 38Torrent Pharmaceuticals LtdTORNTPHARM · quiet · Most evidence points down · 100% evidence34.2out of 100
- 39Natco Pharma LtdNATCOPHARM · quiet · Most evidence points down · 90% evidence31.9out of 100
- 40Dr Reddys Laboratories LtdDRREDDY · breaking out · Most evidence points down · 100% evidence30.4out of 100
- 41Cipla LtdCIPLA · quiet · Most evidence points down · 100% evidence27.9out of 100
- 42Biocon LtdBIOCON · basing · Most evidence points down · 100% evidence22.7out of 100
- 43Syncom Healthcare LtdSYNCOM · Too little evidence to rank firmly · 17% evidence42.4out of 100
- 44Sai Parenterals LtdSAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence38.3out of 100
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Pharma - Formulators, all 44 compared on one page.
Which companies are close to Emcure Pharmaceuticals in size?
Emcure Pharmaceuticals is the 13th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Alkem Laboratories, Biocon and Ipca Laboratories. Just below it: Ajanta Pharma, J B Chemicals & Pharmaceuticals and Wockhardt.
Pharma - Formulators companies close in size
- Alkem Laboratories Ltd ₹62,443 crore
- Biocon Ltd ₹58,987 crore
- Ipca Laboratories Ltd ₹47,039 crore
- Emcure Pharmaceuticals Ltd ₹44,294 crore
- Ajanta Pharma Ltd ₹40,910 crore
- J B Chemicals & Pharmaceuticals Ltd ₹38,677 crore
- Wockhardt Ltd ₹32,934 crore
All 44 Pharma - Formulators companies, largest first
Companies close in size in other industries
- Mphasis Ltd ₹45,808 crore · IT - Software
- Glaxosmithkline Pharmaceuticals Ltd ₹44,692 crore · Pharma - MNC bulk Drugs
- Emcure Pharmaceuticals Ltd ₹44,294 crore
- Balkrishna Industries Ltd ₹44,200 crore · Tyres & Tubes
- Poonawalla Fincorp Ltd ₹44,150 crore · Conglomerate Backed NBFC
What else do people ask about Emcure Pharmaceuticals?
What is Emcure Pharmaceuticals's share price today?
Emcure Pharmaceuticals Ltd's share price is ₹2,334.80, +72.4% over the past year. The whole company is worth ₹44,288 Cr on the market.
In the last 52 weeks it traded between ₹1,355 to ₹2,362; today it is 97% of the way up from the low, 30.9% above its 200-day average (as of 18 November 2026).
What were Emcure Pharmaceuticals's latest quarterly results?
Emcure Pharmaceuticals Ltd reported revenue of ₹2,820 Cr and net profit of ₹325 Cr for the Sep 2026 quarter. Revenue rose 24.2% and profit rose 29.5% compared with a year earlier. Earnings per share were ₹17.16.
The operating margin was 20.9%, 0.0 percentage points higher than a year earlier (as of 18 November 2026).
What is Emcure Pharmaceuticals's market cap?
Emcure Pharmaceuticals Ltd's market capitalisation is ₹44,288 Cr at a share price of ₹2,334.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).
How is Emcure Pharmaceuticals performing?
Emcure Pharmaceuticals Ltd's share price has been rising for 71 weeks. In its latest quarter, revenue rose 24.2% and profit rose 29.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 5 weeks running (as of 18 November 2026).
Will Emcure Pharmaceuticals's share price go up?
This page does not forecast Emcure Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹2,334.80, and it has been rising for 71 weeks. Its P/E of 40.5× is higher than 77% of its own last 2 years (as of 18 November 2026).
Who owns Emcure Pharmaceuticals?
Promoters own 77.8% of Emcure Pharmaceuticals Ltd, foreign institutions 4.9%, domestic institutions 8.5% and the public 8.8% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 4.5 percentage points over 8 quarters (as of 18 November 2026).
Does Emcure Pharmaceuticals have too much debt?
Emcure Pharmaceuticals Ltd has a moderate amount of debt: its debt is 0.34× its equity, and its operating profit is 11 times its interest bill. At Sep 2026 borrowings were ₹1,791 Cr against equity of ₹5,344 Cr.
Keep that borrowing in mind when reading the returns on this page (as of 18 November 2026).
Where is Emcure Pharmaceuticals in its business cycle?
Emcure Pharmaceuticals Ltd's FY26 operating margin was 19.0%, against a 8-year range of 14.0% to 24.2%. The latest quarter was 20.9%, the middle of its own range, neither a peak nor a low.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).
What could break the Emcure Pharmaceuticals story?
The main question: the share price moved +72.4% in a year while earnings per share (last four quarters) moved +37.7%. The difference came from the market paying a higher multiple.
On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).
Is Emcure Pharmaceuticals a stock worth studying right now?
What the numbers show: Emcure Pharmaceuticals Ltd's share price has risen faster than its earnings: +72.4% in a year, against +37.7% for earnings per share. The main open question: whether earnings grow into a price that has already moved.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).
Is there a Emcure Pharmaceuticals share price forecast for 2026?
What management itself guided: FY27 consolidated revenue growth above 20%.
Where does this page get Emcure Pharmaceuticals' management information?
From Emcure Pharmaceuticals' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results.
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.